Menu

NIIMBL

ABOUT NIIMBL

NIIMBL, established under the University of Delaware by the Department of Commerce, focuses on enabling more efficient and flexible manufacturing capabilities for existing and emerging biopharmaceutical products, and developing a world-leading biopharmaceutical manufacturing workforce and their roadmap for biomanufacturing.

Their roadmap for the manufacturing needs and propose a vision of the future for three key topics areas:

  • (1) Vaccines
  • (2) Antibody-Drug Conjugates (ADC) and Bi-specific Antibodies
  • (3) Gene Therapies

For more information on membership, please visit here

 

Staying Current with NIMBL:

October 15th - NIIMBL recently launched its Annual Report, highlighting their community of more than 150 members working to advance the biopharmaceutical industry. 

View the report here

July 31st - NIIMBL has announced recently funded projects sharing about $9 million in grants from the National Institute of Standards and Technology. The money comes from the first round of the Coronavirus Aid, Relief and Economic Security (CARES) Act. The projects address a variety of challenges, including:

  • Serological testing

  • Rapid development of diagnostic testing capabilities

  • Domestic supply-chain problems

  • Approaches to quick decontamination of clinical and public spaces

  • Accelerating the manufacture of medical therapies and rapid-release testing of biopharmaceuticals and vaccines.

Two critical manufacturing testbeds also are planned that will lay the groundwork for many future projects.

 Read more here 

July 17th - NIIMBL is actively working to aid in the fight against COVID-19. This month, the institute announced it had provided funding to the Texas A&M Engineering Experiment Station's (TEES) National Center for Therapeutics Manufacturing (NCTM) to help find a way to prevent the SARS-CoV-2 virus from binding to cells, protecting patients from future infections.

NCTM is producing spike proteins to identify antibodies that can attach to the SARS-CoV-2 spike protein receptor-binding domain and prevent the virus from binding to key sites, thus obstructing the virus from entering and infecting human cells.

Read more about this initiative here

July 3rd - NIIMBL currently has 54 differing projects with call for proposals open. Find out about three currently highlighted by NIMBL as well as a link to view all of the current project opportunities: 

  1. Adaptive Process Control and Advanced Sensing for Robust mAb Glycan Quality. 

  1. Single-use Center of Excellence Based on a Simulated-GMP Process for mAb Production. 

  1. SPIDER Network for Automation Training.